Results 241 to 250 of about 411,515 (387)

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner   +7 more
wiley   +1 more source

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinion

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Emerging strategies for the treatment of advanced non‐small cell lung cancer (NSCLC) featuring epidermal growth factor receptor (EGFR) mutations are helping improve patient outcomes. Which strategies are optimal to effectively manage EGFR‐mutant NSCLC, however, remains unclear.
Gee‐Chen Chang   +13 more
wiley   +1 more source

Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Fluoropyrimidines, a key component of chemotherapy regimens for a variety of solid tumors, can cause severe toxicity. Patients who have specific genetic variants in the DPYD gene, which encodes an enzyme that inactivates fluoropyrimidines, have increased susceptibility to this toxicity.
Sofía L. J. Peeters   +12 more
wiley   +1 more source

Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy. Methods A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.
Joshua S Cheruvathur   +7 more
wiley   +1 more source

Long‐Term Survival After Chemoradiotherapy for Renal Pelvis Cancer

open access: yesIJU Case Reports, EarlyView.
ABSTRACT Introduction Despite the recent increase in applicable chemotherapy regimens for renal pelvic and ureteral cancer, patients with metastases still exhibit a poor prognosis. Here, we report a patient with renal pelvic cancer for whom long‐term survival was achieved using chemoradiotherapy.
Yukinobu Shimada   +8 more
wiley   +1 more source

THROMBOCYTOPENIA WITH ABSENT RADIUS (TAR)

open access: bronze, 1969
Judith G. Hall   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy